Press release
Chronic Obstructive Pulmonary Disease Market 2022 Assurance – by Abbott, AstraZeneca, Dr. Reddy’s Laboratories Ltd, F. Hoffmann-La Roche Ltd, etc
Chronic Obstructive Pulmonary Disease Market
The global chronic obstructive pulmonary disease market has been segmented into medicines, treatments, types, and lastly region. On the basis of medicines, this market has been segmented into antibiotics, bronchodilators, combination inhalers, inhaled steroids, oral steroids, phosphodiesterase-4 inhibitors, and theophylline. Antibiotics are useful for fighting bacterial infections. Bronchodilators are medications that open (dilate) the airways (bronchial tubes) of the lung by relaxing bronchial muscles. They allow people with difficulty in breathing to breathe better. A combination inhaler combines two kinds of medicine in one device. Usually, in a combination inhaler, one medicine is corticosteroid while the other is a bronchodilator. Advair Diskus, Breo, Dulera, and Symbicort are some examples of combination inhalers. Some examples of inhaled steroids include Arnuity Ellipta, Flovent, Pulmicort, Qvar, and Symbicort are some examples of inhaled steroids. Oral steroids are the non-narcotic type of powerful prescription medication. Commonly called as a PDE4 inhibitor, phosphodiesterase type 4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4).
Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1612
Key Players for Global Chronic Obstructive Pulmonary Disease Market
Market Research Future (MRFR) recognizes the following companies as the key players in Chronic Obstructive Pulmonary Disease Market: There are plenty of large and small market players which operate in this market all over the globe.
The key players in global COPD market are Abbott (USA), AstraZeneca (UK), Dr. Reddy’s Laboratories Ltd (India), F. Hoffmann-La Roche Ltd (Switzerland), GSK (UK), Merck (USA), Novartis AG (Switzerland), and Pfizer Inc (USA).
Latest Industry News
Pulmonx® Corp. has announced that the US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients. The Zephyr Valve is the first minimally-invasive device approved in the USA for treating emphysema patients. 30 JUNE 2018
The FDA’s Pulmonary Allergy Drugs Advisory Committee has voted 16-3 against recommending GlaxoSmithKline’s mepolizumab (Nucala) as an add-on treatment to inhaled corticosteroid-based maintenance treatments that claim to reduce flare-ups in patients with COPD. 25 JUL 2018
Regional Analysis for Global Chronic Obstructive Pulmonary Disease Market
The regional segmentation of Global Chronic Obstructive Pulmonary Disease Market covers The Americas (North America & South Americas), Europe, Asia Pacific, and Middle East & Africa (MEA). Among the Americas, North America is the bigger market for COPD, than South America due to advanced medical facilities and more investment in this region, the biggest local markets are the United States of America (USA) and Canada. North America is the largest market among all regional markets.
Due to the reasons same as the Americas, Western Europe is the bigger market, than Eastern Europe. Although the market in whole Europe is decent and steady in Western Europe, the cream of Europe market in France, Germany, Italy, Spain, and the United Kingdom (UK). Europe is the second largest market for COPD.
In the Asia Pacific region, the market is growing due to the high density of population and improving medical facilities in some countries of this region. During the forecast period, Asia Pacific is expected to be the fastest growing market for COPD. The biggest markets in the Asia Pacific are Australia, China, India, Japan, and South Korea, followed by the rest of the Asia Pacific. In the MEA region, the market is small due to poor or limited infrastructure and less investment in health care. However, due to hookah smoking, the number of people suffering from COPD is sizable. In this region, the biggest markets are Kuwait, Oman, Saudi Arabia, United Arab Emirates (UAE) and Qatar.
Browse Complete Report @ https://www.marketresearchfuture.com/reports/chronic-obstructive-pulmonary-disease-copd-market-1612
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Obstructive Pulmonary Disease Market 2022 Assurance – by Abbott, AstraZeneca, Dr. Reddy’s Laboratories Ltd, F. Hoffmann-La Roche Ltd, etc here
News-ID: 1330570 • Views: …
More Releases from Market Research Future
Hydrofluoric Acid Market (CAGR) of 4%, Innovation Imperative Future Proofing You …
Hydrofluoric acid (HF) is a crucial chemical compound with a wide range of applications across various industries. Despite its hazardous nature, it plays an essential role in manufacturing processes, especially in the production of fluorine compounds. The global hydrofluoric acid market has been witnessing steady growth, driven by demand from end-user industries such as oil refining, pharmaceuticals, and electronics.
The Hydrodesulfurization Catalysts Market is projected to register a CAGR of over…
Palm Methyl Ester Derivative Market Size Projected to Grow at 5.92% CAGR, Reachi …
In recent years, the global market for palm methyl ester derivatives has witnessed significant growth, driven by various factors including environmental concerns, technological advancements, and the increasing demand for sustainable alternatives in various industries. Palm methyl ester derivatives, derived from palm oil, have emerged as versatile ingredients with applications spanning across sectors such as cosmetics, pharmaceuticals, lubricants, and more.
The Palm Methyl Ester Derivative Market Size was valued at USD 1.5…
Asia-Pacific Ceramic Tiles Market to Register Highest CAGR Growth of 7.50% by 20 …
The Asia-Pacific ceramic tiles market has been witnessing robust growth, driven by various factors such as increasing investments in residential and commercial construction, renovation activities, and the growing preference for aesthetically pleasing and durable flooring solutions. Countries like China, India, Japan, and South Korea have been leading the market growth, supported by strong manufacturing capabilities, technological advancements, and evolving consumer preferences.
Asia-Pacific Ceramic Tiles Market Size was valued at USD 141.2…
APAC Wallpaper Market to Register Highest CAGR Growth of 8% by 2032: Analysis by …
The APAC wallpaper market has witnessed significant growth in recent years, driven by factors such as rising disposable incomes, expanding construction activities, and growing awareness regarding interior decor. Countries like China, India, Japan, South Korea, and Australia have emerged as key contributors to the region's wallpaper market. Additionally, the increasing adoption of innovative wallpaper designs and patterns is fueling market growth further.
APAC Wallpaper Market Size was valued at USD 0.55…
More Releases for Pulmonary
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Embolism - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Pulmonary Embolism - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Embolism - Pipeline Review, H2 2017, provides an overview of the Pulmonary Embolism (Cardiovascular) pipeline landscape.
Pulmonary embolism is the sudden blockage of a major blood vessel (artery) in the lung, usually by a blood…
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot
The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
